显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭






BioDuro 迈向CRO之路  

2009-05-11 13:19:09|  分类: Bio-Pharma |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |



燕子BioDuro 迈向成功CRO之路

China's one stop research shop

19 May 2008

John Oyler has founded a string of startups in the US, including Genta, a biotech specializing in cancer drug discovery, and Galenea, which focuses on treatments for psychiatric diseases. But in 2005 he chose China as his base to launch BioDuro, a life sciences Contract Research Organisation (CRO). He explains to Chemistry World how he has managed to turn BioDuro into one of China's leading CROs in just three years.

Why did you choose to launch a CRO in China rather than the US?

In the US over the last five years, the big pharmaceutical companies and venture capital firms have cut investment in the longer-term, riskier preclinical research that is likely to lead to truly innovative therapies.

On the other hand, building a CRO in the emerging Chinese market allows us to be involved in all stages of the research, from the basic idea to the clinical trial.

When I was CEO of Galenea about a quarter of our researchers were from India and a third from China. This made me realise that China could supply exceptionally capable scientists.

So my old friend and business partner Ma*** Tayebi and I launched and financed BioDuro. Funding our business ourselves allowed us to pursue the opportunities that we thought were the most important.

But why did you choose Beijing, when the main clients of CROs - the big multinational drug firms - have their R&D centres in Shanghai?

There are exceptionally talented scientists in Beijing. It has world class universities and research institutes, like Peking and Tsinghua universities, Peking Union Medical College, the National Institute of Biological Sciences, the National Center for the Safety Evaluation of Drugs, and the related institutes of the Chinese Academy of Sciences.

R&D centres, which only do some of big pharma's drug development work, are not the only source of business. Most of our contracts are from their US and European headquarters. And because there are fewer research organisations and CROs in Beijing, there is more chemistry and biology talent available to draw on.

By the end of this year, we will have nearly 600 chemists and biologists working for the company. Most of the world's top pharmaceutical firms are our clients. We have our business and marketing headquarters in San Diego, California. We have a team of more than 20 senior scientists leading the firm, many of whom used to be at multinationals like Merck and Pfizer.

Is it easy to attract top scientists to China?

Most are overseas Chinese who had long wanted to contribute the scientific development of their home country once there were suitable opportunities. And I am always on a mission to persuade the best scientist join us.

One example is a senior scientist at Merck - Steven Hutchins. I first met him when he gave a talk [in the US] about life science development. Then, after his talk we had a long talk and he saw that our work here was aligned with his vision. Later, after we met in China, he decided to join us. Likewise Jason Zhang joined us recently from Neurocrine in San Diego where he has watched us grow over the last few years. Jason returned for the opportunity [to work for BioDuro], but also to be closer to his parents and family. For the senior scientists, they understand that there may be more responsibility and better research opportunities in China.

Multinationals choose Chinese CROs to keep costs down, but you have spent a lot of money hiring scientists and establishing facilities. Do you still have the cost advantage?

First I would say big pharma is not entirely driven by costs. It also depends on the quality of work you can offer and whether they want an integrated solution or simply some easy research.

The cost of doing research here can be a third to a quarter of that in the US or Europe. Sure - BioDuro will not be the cheapest option, but we have already established a strong reputation for providing integrated solutions, creative problem solving, adhering to environmental, health, and safety standards, and exceeding client expectations.

But the best thing about doing research in China is the scientists. They have a real thirst for knowledge, and an incredibly humble, yet can-do approach to challenges. There is nothing that they cannot learn and no challenge that cannot be overcome.

I think all of these factors stimulate multinational pharmaceuticals to engage in contract research in China - not costs alone.

Hepeng Jia

John Oyler's BioDuro is already one of China's leading Contract Research Organisations (CROs) ? BioDuro


BioDuro 迈向成功CRO之路

John Oyler在美国建立了一系列新公司,包括Genta(一家专门开发抗癌药物的生物科技公司)和Galenea(专门从事治疗精神疾病)。但是2005年他选择在中国创建BioDuro公司――一家生命科学研究外包服务机构(CRO)。他向《化学世界》杂志阐述了,他如何在短短三年时间内将BioDuro变成中国CRO的领军人物。



当我还是Galenea的CEO时,我们的研究人员约有四分之一来自于印度,三分之一来自于中国。这使我意识到中国能提供非常有才华的研究人员。因此我的老朋友及生意伙伴Ma*** Tayebi和我组建了这家BioDuro。为了增强我们的业务,我们追求我们认为最重要的机会。







Steven Hutchins曾是默克公司的一位资深研究员。我第一次遇到他(在美国)是在他关于生命科学发展的一次演讲上。在他演讲结束后,我们进行了一次长谈,他发现我们在这儿(中国)的工作与他的设想吻合。后来,当我们在中国又一次见面以后,他决定加入我们。同样,Jason Zhang最近也离开圣地亚哥的Neurocrine公司而加入了我们,他目睹了我们在近年内的成长。因为在BioDuro的这个工作机会,Jason回到了中国,同时也是为了离父母和家人更近。对于高级研究员,他们明白在中国工作要承担更多责任,也有更好的研究机会。






阅读(466)| 评论(0)



<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->


网易公司版权所有 ©1997-2018